Francis M Sirotnak
Overview
Explore the profile of Francis M Sirotnak including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
159
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dabrowska M, Sirotnak F
Acta Biochim Pol
. 2017 Jun;
64(2):371-374.
PMID: 28612064
ABCC10 (MRP7) plays a role in cellular detoxification and resistance to anticancer drugs. Since ABCC10 gene transcription in human prostate cancer CWR22Rv1 cells was found dependent on E2F binding sequence...
2.
Riely G, Rizvi N, Kris M, Milton D, Solit D, Rosen N, et al.
J Clin Oncol
. 2008 Dec;
27(2):264-70.
PMID: 19047285
Purpose: A prior study demonstrated that addition of continuous daily erlotinib fails to improve response rate or survival in non-small-cell lung cancer (NSCLC) patients treated with carboplatin and paclitaxel. However,...
3.
Lee M, She Y, Soskis M, Borella C, Gardner J, Hayes P, et al.
J Clin Invest
. 2004 Oct;
114(8):1107-16.
PMID: 15489958
Peptide deformylase activity was thought to be limited to ribosomal protein synthesis in prokaryotes, where new peptides are initiated with an N-formylated methionine. We describe here a new human peptide...
4.
Dabrowska M, Sirotnak F
Gene
. 2004 Oct;
341:129-39.
PMID: 15474296
Studies focusing on the transcriptional regulation of MRP7 (multidrug resistance associated protein 7) gene expression in human tumor cells are described. As shown by real-time RT-PCR, expression of the MRP7...
5.
Jung C, Motwani M, Kortmansky J, Sirotnak F, She Y, Gonen M, et al.
Clin Cancer Res
. 2003 Dec;
9(16 Pt 1):6052-61.
PMID: 14676132
Purpose: Flavopiridol is a cyclin-dependent kinase inhibitor currently under development by the National Cancer Institute both as a single agent and in combination with chemotherapy. There have been numerous reports...
6.
Lee M, Antczak C, Li Y, Sirotnak F, Bornmann W, Scheinberg D
Biochem Biophys Res Commun
. 2003 Nov;
312(2):309-15.
PMID: 14637138
Peptide deformylases (PDFs) have been investigated as potential specific targets for antibiotics, but the possible existence of a functional human PDF (HsPDF) presents a potential hurdle to the design of...
7.
Sirotnak F
Semin Oncol
. 2003 Mar;
30(1 Suppl 1):12-20.
PMID: 12644980
ZD1839 (Iressa; AstraZeneca Pharmaceuticals LP, Wilmington, DE) is an orally active, selective inhibitor of epidermal growth factor receptor-tyrosine kinase (EGFR-TK) that blocks signaling pathways responsible for driving proliferation, invasion, and...
8.
Sirotnak F, She Y, Lee F, Chen J, Scher H
Clin Cancer Res
. 2002 Dec;
8(12):3870-6.
PMID: 12473602
Purpose: These studies examined the effect of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ("Iressa")(3) on CWR22 prostate tumors in nude mice. The effect of ZD1839 was...
9.
Motwani M, Sirotnak F, She Y, Commes T, Schwartz G
Cancer Res
. 2002 Jul;
62(14):3950-5.
PMID: 12124325
Treatment of the human colon cancer cells Hct116 with SN-38 (an active metabolite of CPT-11) resulted in G2 cell cycle arrest without induction of apoptosis. However, subsequent treatment of SN-38-treated...